Resveratrol suppresses expression of VEGF by human retinal pigment epithelial cells: Potential nutraceutical for age-related macular degeneration

Aging and Disease

Volumn 5, Issue 2, 2014, Pages 88-100

  Nagineni, Chandrasekharam N ^a   Raju, Raghavan ^b   Nagineni, Krishnasai K ^c   Kommineni, Vijay K ^a   Cherukuri, Aswini ^a   Kutty, R Krishnan ^a   Hooks, John J ^a   Detrick, Barbara ^d  

^a NATIONAL EYE INSTITUTE   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Age related macular degeneration; Cytokines; Resveratrol; Retina; Retinal pigment epithelium; SIRT1; VEGF

Indexed keywords

CYTOKINE; ENDOSTATIN; GAMMA INTERFERON; INTERLEUKIN 1BETA; MESSENGER RNA; NUTRACEUTICAL; RESVERATROL; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN C;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CELL CULTURE; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; NEOVASCULARIZATION (PATHOLOGY); PIGMENT EPITHELIUM; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WOUND CLOSURE;

RICE STRIPE VIRUS;

EID: 84908170519     PISSN: None     EISSN: 21525250     Source Type: Journal    
DOI: 10.14336/AD.2014.050088     Document Type: Article

References (66)

1. Ambati J, Fowler BJ (2012). Mechanisms of age-related macular degeneration. Neuron, 75: 26-39.
2. Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J (2004). Prevalence of age-related macular degeneration in the United States. Arch Ophthal, 122:564-572.
3. Klein R, Chou CF, Klein BE, Zhang X, Meuer SM, Saaddine JB (2011). Prevalence of age-related macular degeneration in the US population. Arch. Ophthalmol, 129: 75-80.
4. Swaroop A, Chew EY, Rickman CB, Abecasis GR (2009). Unraveling a multifactorial late-onset disease: From genetic susceptibility to disease mechanisms for age-related macular degeneration. Annu Rev Genomics Human Genet, 10:19-43.
5. Young RW (1987). Pathophysiology of age-related macular degeneration. Sur Ophthal, 31:291-306.
6. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF (2001). An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Ret Eye Res 20:705-732.
7. Das A, McGuire PG (2003). Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Ret Eye Res, 22:721-748.
8. Campochiaro PA (2013). Ocular neovascularization. J. Mol. Med, 91: 311-321.
9. Zarbin MA (2004). Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthal, 122:598-614.
10. Marmor MF and Wolfensberger TJ (1998). The retinal pigment epithelium, fuction and disease. New York: Oxoford University Press.
11. Strauss O (2005). The retinal pigment epithelium in visual function. Physiol Rev, 85:845-881.
12. Bok D (1993). The retinal pigment epithelium: a versatile partner in vision. J Cell Sci Suppl 17:189-195.
13. Nagineni CN, Detrick B, Hooks JJ (1994). Synergistic effects of gamma interferon on inflammatory mediators that induce interleukin-6 gene expression and secretion by human retinal pigment epithelial cells. Clin Diag Lab Immunol, 1: 569-577.
14. Nagineni CN, Samuel W, Nagineni S, Pardhasaradhi K, Wiggert B, Detrick B, Hooks JJ (2003). Transforming growth factor-beta induces expression of vascular endothelial growth factor in human retinal pigment epithelial cells: involvement of mitogen-activated protein kinases. J Cell Physiol, 197:453-462.
15. Nagineni CN, Kutty V, Detrick B, Hooks JJ (2005). Expression of PDGF and their receptors in human retinal pigment epithelial cells and fibroblasts: Regulation by TGF-ß. J Cell Physiol, 203: 35-43.
16. Nagineni CN, Cherukuri KS, Kutty V, Detrick B, Hooks JJ (2007). Interferon-gamma differentially regulates TGF-beta1 and TGF-beta2 expression in human retinal pigment epithelial cells through JAK-STAT pathway. J Cell Physiol, 210:192-200.
17. Nagineni CN, Kommineni VK, William A, Hooks JJ, Detrick B (2010). IL-11 expression in retinal and corneal cells is regulated by interferon-g. Biochem Biophys Res Commun, 391: 287-292.
18. Nagineni CN, Kommineni VK, William A, Detrick B, Hooks JJ (2012). Regulation of VEGF expression in human retinal cells by cytokines: Implications for the role of inflammation in age-related macular degeneration, J Cell Physiol, 227:116-126.
19. Hooks JJ, Nagineni CN, Hooper LC, Hayashi K, Detrick B (2008). IFN-beta provides immuno-protection in the retina by inhibiting ICAM-1 and CXCL9 in retinal pigment epithelial cells. J Immunol, 180:3789-3796.
20. Marneros AG, Fan J, Yokoyama Y, Gerber HP, Ferrara N, Crouch RK, Olsen BR (2005). Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol, 167:1451-1459.
21. Bhutto I, Lutty G (2012). Understanding age-related macular degeneration (AMD) Relationships between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris complex. Mol. Aspec Med, 33:295-317.
22. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR (1996). Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthal Vis Sci, 37:855-868.
23. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT (1997). Increased expression of angiogenic growth factors in age-related maculopathy. Brit J Ophthal, 81:154-162.
24. Amin R, Puklin JE, Frank RN (1994). Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Invest Ophthal Vis Sci, 35:3178-3188.
25. Grossniklaus HE, Ling JX, Wallace TM, Dithmar S, Lawson DH, Cohen C, Elner VM, Elner SG, Sternberg P, Jr (2002). Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis, 8:119-126.
26. Noel A, Jost M, Lambert V, Lecomte J, Rakic JM (2007). Anti-angiogenic therapy of exudative age-related macular degeneration: current progress and emerging concepts. Trend Mol Med, 13:345-352.
27. Zhang SX, Ma JX (2007). Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy. Prog Ret Eye Res, 26:1-37.
28. Kovach JI, Schwartz SG, Flynn Jr HW, Scott IU (2012). Anti-VEGF treatment strategies for wet AMD. J Ophthal, 2012: ID 786870, 7 pages
29. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME (2008). Vascular endothelial growth factor in eye disease. Prog Ret Eye Res, 27:331-371.
30. Ferrara N, Gerber HP, LeCouter J (2003). The biology of VEGF and its receptors. Nat Med, 9:669-676.
31. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA (1991). The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Bio Chem, 266:11947-11954.
32. Chilov D, Kukk E, Taira S, Jeltsch M, Kaukonen J, Palotie A, Joukov V, Alitalo K (1997). Genomic organization of human and mouse genes for vascular endothelial growth factor C. J Biol Chem, 272:25176-25183.
33. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K (1996). A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J, 15(7):1751.
34. Weis SM, Cheresh DA (2005). Pathophysiological consequences of VEGF-induced vascular permeability. Nature, 437:497-504.
35. Delmas D, Aires V, Limagne E, Dutartre P, Mazue F, Ghiringhelli F, Latruffe N (2011). Transport, stability, and biological activity of resveratrol. Ann. N.Y. Acad. Sci, 1215: 48-59.
36. Williams LD, Burdock GA, Edwards JA, Beck M, Bausch J (2009). Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem Toxicol, 47: 2170-2182.
37. Pervaiz S, Holme AL (2009). Resveratrol: its biologic targets and functional activity. Antioxid Redox Sig. 11: 2851- 2893.
38. Harikumar KB, Aggarwal BB (2008). Resveratrol. A multitargeted agent for age-associated chronic diseases. Cell Cycle, 7: 1020-1035.
39. Brakenhielm E, Cao R, Cao Y (2001). Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J express, 10.1096/fj.01-0028fje.
40. Jian B, Yang S, Chaudry IH, Raju R (2012). Resveratrol improves cardiac contractility following trauma-hemorrhage by modulating sirt1. Mol Med, 18: 209-214.
41. Chung S, Yao H, Caito S, Hwang J-W, Arunachalam G, Rahman I (2010). Regulation of SIRT1 in cellular functions: Role of polyphenols. Arch Biochem Biophys, 501:79-90.
42. Finkel T, Deng C-X, Mostoslavsky R (2009). Recent progress in the biology and physiology of sirtuins. Nat Rev, 460: 587- 591.
43. Cheng H-L, Mostoslavsky R, Salto S, Manis JP, Gu Y, Patel P, Bronson R, Appella E, Alt FW, Chua KF (2003). Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Nat Acad Sci USA, 100: 10794-10799.
44. Ambati J, Atkinson JP, Gelfand BD (2013). Immunology of age-related macular degeneration. Nat Rev, 13: 438-451.
45. Penfold PL, Madigan MC, Gillies MC, Provis JM (2001). Immunological and aetiological aspects of macular degeneration. Prog Ret Eye Res, 20:385-414.
46. Nussenblatt RB, Ferris F, 3rd (2007). Age-related macular degeneration and the immune response: implications for therapy. Am J Ophthal, 144:618-626.
47. Whitcup SM, Sodhi A, Atkinson JP, Holers VM, Sinha D, Rohrer B, Dick AD (2013). The role of the immune response in age-related macular degeneration. Int J Inflam, 2013: ID 348092, 10 pages
48. Anderson DH, Mullins RF, Hageman GS, Johnson LV (2002). A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthal, 13:411-431.
49. Bressler NM, Silva JC, Bressler SB, Fine SL, Green W (1994). Clinicopathologic correlation of drusen and retinal pigment epithelial abnormalities in age-related macular degeneration. Retina, 14:130-142.
50. Donoso LA, Kim D, Frost A, Callahan A, Hageman G (2006). The role of inflammation in the pathogenesis of age-related macular degeneration. Surv Ophthal, 51:137-152.
51. Bhutto IA, McLeod DS, Hasegawa T, Kim SY, Merges C, Tong P, Lutty GA (2006). Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp Eye Res, 82:99-110.
52. Weikel KA, Chiu C-J, Taylor A (2012). Nutritional modulation of age-related macular degeneration. Mol. Aspects Med, 33: 318-375.
53. Chew EY, Lindblad AS, Clemons T (2009). Summary results and recommendations from the age-related eye disease study. Arch. Ophthalmol, 127: 1678-1679.
54. Schleicher M, Weikel K, Garber C, Taylor A (2013). Diminishing risk for age-related macular degeneration with nutrition: A current view. Nutrients 5: 2405-2456.
55. Kansagara D, Gleitsmann D, Gillingham M, Freeman M, Quinones A (2011). Nutritional supplements for age-related macular degeneration. A Systema Rev VA-ESP Project #05-225.
56. Khan AA, Dace DS, Ryazanov AG, Kelly J, Apte RS (2010). Resveratrol regulates pathologic angiogenesis by a eukaryotic elongation factor-2 kinase-regulated pathway. Am J Pathol, 177:481-492.
57. Pintea A, Rugina D, Pop R, Bunea A, Socaciu C, Diehl HA (2011). Antioxidant effect of trans-resveratrol in cultured human retinal pigment epithelial cells. J Ocu Phar Thera, 27: 315- 321.
58. King RE, Kent KD, Bomser JA (2005). Resveratrol reduces oxidation and proliferation of human retinal pigment epithelial cells via extracellular signal regulated kinase inhibition. Chem. Biol Inter, 151:143-149.
59. Kannan R, Zhang N, Sreekumar PG, Spee CK, Rodriguez A, Barron E, Hinton DR (2006). Stimulation of apical and basolateral vascular endothelial growth factor-A and vascular endothelial growth factor-C secretion by oxidative stress in polarized retinal pigment epithelial cells. Mol Vis. 12:1649-1659.
60. Maminishkis A, Chen S, Jalickee S, Banzon T, Shi G, Wang FE, Ebalt T, Hammer JA, Miller SS (2006). Confluent monolayers of cultured human fetal retinal pigment epithelium exhibit morphology and physiology of native tissue. Invest Ophthalmol Vis Sci 47: 3612-3620.
61. Sonada S, Sreekumar PG, Kase S, Spee C, Ryan SJ, Kannan R, Hinton DR (2010). Attainment of polarity promotes growth factor secretion by retinal pigment epithelial cells: Relevance to age-related macular degeneration. Aging 2:28-42.
62. Ablonczy Z, Dabrouj M, Tang PH, Liu Y, Sambamurthi K, Marmorstein AD, Crosson CE (2011). Human retinal pigment epithelium cells as functional models for the RPE in vivo. Invest Opthalmol Vis Sci 52: 8614-8620.
63. Li R, Wen R, Banzon T, Maminishkis A, Miller SS (2011). CNTF mediates neurotrophic factor secretion and fluid absorption in human retinal pigment epithelium. PLoS ONE 6(9) e23148.
64. Kelly G (2010). A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 1. Altern Med Rev, 15: 245-263.
65. Baur JA, Sinclair DA (2006). Therapeutic potential of resveratrol: the in vivo evidence. Nat, Rev, Drug Discov, 5: 493-506.
66. Richer S, Stiles W, Ulanski L, Carroll D, Podella C (2013). Observation of human retinal remodeling in octogenarians with a resveratrol based nutritional supplement. Nutrients, 5: 1989-2005.